Scholar Rock Holding (SRRK) EBITDA Margin (2019 - 2022)
Scholar Rock Holding (SRRK) recorded quarterly EBITDA Margin of 24.3% in Q1 2022, up 97.26% quarter-over-quarter from 887.85% in Q4 2021, and up 56291.0% on a YoY basis from N/an in Q1 2021.
Scholar Rock Holding (SRRK) EBITDA Margin (2019 - 2022) Analysis & Trends
Scholar Rock Holding's EBITDA Margin history runs 4 years deep, the most recent figure standing at 24.3% for Q1 2022.
- In Q1 2022, EBITDA Margin rose 56291.0% year-over-year to 24.3%; the TTM figure through Dec 2022 stood at 407.77% (up 29287.0% YoY), while the FY2022 annual figure was 407.77%, up 29287.0% from the prior year.
- EBITDA Margin was 24.3% for Q1 2022 at Scholar Rock Holding, up from 887.85% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 24.3% in Q1 2022 to a low of 887.85% in Q4 2021.
- Historically, EBITDA Margin has averaged 486.51% across 4 years, with a median of 499.13% in 2020.
- The sharpest annual moves came in 2020 and 2022: EBITDA Margin tumbled 62078 bps in 2020, then surged 56291 bps in 2022.
- A 4-year view of EBITDA Margin shows it stood at 152.67% in 2019, then slumped by 407 bps to 773.46% in 2020, then decreased by 15 bps to 887.85% in 2021, then surged by 97 bps to 24.3% in 2022.
- The last three EBITDA Margin figures came in at 24.3% (Q1 2022), 887.85% (Q4 2021), and 686.6% (Q3 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -24.30% |
| Dec 31, 2021 | -887.85% |
| Sep 30, 2021 | -686.60% |
| Jun 30, 2021 | -668.57% |
| Mar 31, 2021 | -587.21% |
| Dec 31, 2020 | -773.46% |
| Sep 30, 2020 | -777.31% |
| Jun 30, 2020 | -499.13% |
| Mar 31, 2020 | -335.45% |
| Dec 31, 2019 | -152.67% |
| Sep 30, 2019 | -338.90% |
| Jun 30, 2019 | -247.73% |
| Mar 31, 2019 | -345.49% |